These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026 [TBL] [Abstract][Full Text] [Related]
8. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumors. Antonescu C Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552 [TBL] [Abstract][Full Text] [Related]
10. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624 [TBL] [Abstract][Full Text] [Related]
11. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of an Italian series of sporadic GISTs. Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875 [TBL] [Abstract][Full Text] [Related]
14. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients. Valadão M; Braggio D; Santos AF; Pimenta-Inada HK; Linhares E; Gonçalves R; Romano S; Vilhena B; Small I; Cubero D; Cruz F; Oliveira AT; Martinho O; Reis RM; Guimarães DP; Ferreira CG J Surg Res; 2012 Nov; 178(1):288-93. PubMed ID: 22516345 [TBL] [Abstract][Full Text] [Related]
15. Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression. Chou A; Chen J; Clarkson A; Samra JS; Clifton-Bligh RJ; Hugh TJ; Gill AJ Mod Pathol; 2012 Sep; 25(9):1307-13. PubMed ID: 22555179 [TBL] [Abstract][Full Text] [Related]
16. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423 [TBL] [Abstract][Full Text] [Related]